Sugi Predict

Sugi Predict / Compounds / SCHEMBL2676153

SCHEMBL2676153

SCHEMBL2676153

COC(=O)c1ccc(CCC(/C=C/c2ccccc2OCc2ccc(C(C)(C)C)cc2)Cc2cc(F)c(O)c(F)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 8/20 0.43
▸ MEN1 O00255 6/20 0.43
▸ POLB P06746 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ TP53 P04637 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ RAB9A P51151 5/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 5/20 0.40
▸ MAPT P10636 3/20 0.40
▸ HTT P42858 3/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675613 1.00 KMT2A (0.43) KMT2AMEN1POLBPKMBLM
SCHEMBL2675543 0.92 RXRA (0.43) KMT2AMEN1POLBHPGDRAB9A
SCHEMBL2675539 0.92 RXRA (0.43) KMT2AMEN1POLBHPGDRAB9A
SCHEMBL2675692 0.89 KMT2A (0.40) KMT2AMEN1POLBPKMBLM
SCHEMBL2675685 0.89 KMT2A (0.40) KMT2AMEN1POLBPKMBLM
SCHEMBL2295713 0.85 TP53 (0.47) KMT2AMEN1POLBPKMBLM
SCHEMBL2295707 0.85 TP53 (0.47) KMT2AMEN1POLBPKMBLM
SCHEMBL2290407 0.85 TP53 (0.47) KMT2AMEN1POLBPKMBLM
SCHEMBL2290418 0.85 TP53 (0.47) KMT2AMEN1POLBPKMBLM
SCHEMBL8232753 0.84 KMT2A (0.43) KMT2AMEN1POLBPKMBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173704-B2 Difluorophenol derivatives and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-08 — — US disclosed
US-8173704-B2 Difluorophenol derivatives and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-08 — — US disclosed
US-8173704-B2 Difluorophenol derivatives and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-08 — — US disclosed
US-20090291993-A1 Difluorophenol Derivatives and Their Use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-11-26 — — US disclosed
US-20090291993-A1 Difluorophenol Derivatives and Their Use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-11-26 — — US disclosed
US-20090291993-A1 Difluorophenol Derivatives and Their Use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-11-26 — — US disclosed
WO-2007045369-A1 DIFLUOROPHENOL DERIVATIVES AND THEIR USE BAYER HEALTHCARE AG (DE) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291993-A1 Difluorophenol Derivatives and Their Use TPMT, FABP3, DPP4 KMT2A 1549/4885MEN1 3679/4885POLB 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.